泛癌分析揭示致癌性MET融合的不同病理基因组亚群及其对MET靶向治疗的差异敏感性
该研究分析了来自91,119例患者机构队列中的56例MET融合阳性肿瘤,发现两种MET融合形式:一种为5'端伙伴含同源二聚化结构域并与MET酪氨酸激酶结构域框内融合,对MET酪氨酸激酶抑制剂(TKI)敏感;另一种缺乏伙伴同源二聚化基序并保留MET跨膜和胞外结构域。研究提出融合致癌性和MET TKI敏感性由结构拓扑和病理基因组背景决定。
要点
- MET融合可分为两类:含伙伴同源二聚化结构域且常排除MET外显子14的融合,以及缺乏该结构域但保留MET跨膜和胞外结构域的融合。
- 第一类融合在临床前模型和肺癌患者中对MET TKI敏感;第二类融合多见于胶质瘤并常伴受体酪氨酸激酶共改变。
- I型(克唑替尼、卡马替尼、特泊替尼、赛沃替尼)或II型(卡博替尼)MET TKI对MET融合有效,含伙伴同源二聚化的融合缓解最佳。
核心结论
- MET融合的致癌性和MET TKI敏感性由结构拓扑和病理基因组背景决定。
- 含伙伴同源二聚化结构域的融合对MET TKI敏感,在肺癌中尤为明显。
- 缺乏伙伴同源二聚化基序的融合多见于胶质瘤,并常伴受体酪氨酸激酶共改变。
研究设计与样本
- 机构队列共91,119例患者,包括79,864例DNA测序和11,255例RNA测序,其中56例为MET融合阳性肿瘤。
主要发现
- 第一类融合的5'端伙伴含同源二聚化结构域,与MET酪氨酸激酶结构域框内融合,主要源于易位,常排除MET外显子14,通过细胞质聚集和组成性激活介导致癌,在临床前模型和肺癌患者中对MET TKI显著敏感。
- 第二类融合缺乏伙伴同源二聚化基序,保留MET跨膜和胞外结构域,发病机制涉及染色体内重排,导致启动子劫持的伙伴选择和融合等位基因扩增。
- 膜结合型融合在胶质瘤中富集,并伴有受体酪氨酸激酶共改变。
关键数值与推荐
- I型MET TKI包括克唑替尼、卡马替尼、特泊替尼和赛沃替尼;II型MET TKI包括卡博替尼。
- 含伙伴同源二聚化的融合对MET TKI缓解最佳。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: MET fusions (MET-F) are oncogenic drivers that remain poorly characterized. Analysis of 56 MET-F-positive tumors from an institutional cohort of 91,119 patients (79,864 DNA sequencing plus 11,255 RNA sequencing) uncovered two forms of MET-F pathobiology. The first group featured 5' partners with homodimerization domains fused in-frame with the MET tyrosine kinase domain, primarily originated from translocations, frequently excluded MET exon 14, mediated oncogenesis through cytoplasmic aggregation and constitutive activation, and were markedly sensitive to MET tyrosine kinase inhibitors (TKI) in preclinical models and patients with lung cancer. The second group lacked partner homodimerization motifs and retained MET transmembrane and extracellular domains. Their pathogenesis involved intrachromosomal rearrangements, resulting in partner selection for promoter hijacking and fusion allele amplification. Membrane-bound fusions were enriched in gliomas with receptor tyrosine kinase co-alterations. We provide a framework to comprehend the heterogeneous landscape of MET-Fs, supporting that fusion oncogenicity and MET TKI sensitivity are determined by structural topology and pathogenomic context. SIGNIFICANCE: MET fusions are primary drivers of tumor growth in multiple tumor types - lung cancer and gliomas - and can be effectively targeted with either type I (crizotinib, capmatinib, tepotinib, and savolitinib) or type II (cabozantinib) MET TKIs, with best responses in tumors harboring fusions with partner homodimerization.
引用
- Febres-Aldana CA, Vojnic M, Odintsov I, et al. Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy. Cancer Discov. 2025. PMID: 39965191. doi:10.1158/2159-8290.CD-24-0417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。